JP2018534255A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534255A5
JP2018534255A5 JP2018515550A JP2018515550A JP2018534255A5 JP 2018534255 A5 JP2018534255 A5 JP 2018534255A5 JP 2018515550 A JP2018515550 A JP 2018515550A JP 2018515550 A JP2018515550 A JP 2018515550A JP 2018534255 A5 JP2018534255 A5 JP 2018534255A5
Authority
JP
Japan
Prior art keywords
item
seq
trimer
nos
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534255A (ja
JP6933379B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051966 external-priority patent/WO2017053170A1/en
Publication of JP2018534255A publication Critical patent/JP2018534255A/ja
Publication of JP2018534255A5 publication Critical patent/JP2018534255A5/ja
Priority to JP2021072064A priority Critical patent/JP2021105060A/ja
Application granted granted Critical
Publication of JP6933379B2 publication Critical patent/JP6933379B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515550A 2015-09-24 2016-09-15 転移を低減するための方法および組成物 Expired - Fee Related JP6933379B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021072064A JP2021105060A (ja) 2015-09-24 2021-04-21 転移を低減するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232169P 2015-09-24 2015-09-24
US62/232,169 2015-09-24
PCT/US2016/051966 WO2017053170A1 (en) 2015-09-24 2016-09-15 Methods and compositions for reducing metastases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021072064A Division JP2021105060A (ja) 2015-09-24 2021-04-21 転移を低減するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2018534255A JP2018534255A (ja) 2018-11-22
JP2018534255A5 true JP2018534255A5 (cg-RX-API-DMAC7.html) 2019-10-31
JP6933379B2 JP6933379B2 (ja) 2021-09-08

Family

ID=58386932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515550A Expired - Fee Related JP6933379B2 (ja) 2015-09-24 2016-09-15 転移を低減するための方法および組成物
JP2021072064A Pending JP2021105060A (ja) 2015-09-24 2021-04-21 転移を低減するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021072064A Pending JP2021105060A (ja) 2015-09-24 2021-04-21 転移を低減するための方法および組成物

Country Status (10)

Country Link
US (2) US11219694B2 (cg-RX-API-DMAC7.html)
EP (1) EP3352800B1 (cg-RX-API-DMAC7.html)
JP (2) JP6933379B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180063885A (cg-RX-API-DMAC7.html)
CN (1) CN108289966A (cg-RX-API-DMAC7.html)
AU (1) AU2016328279A1 (cg-RX-API-DMAC7.html)
CA (1) CA2999756A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907486T3 (cg-RX-API-DMAC7.html)
IL (1) IL258292A (cg-RX-API-DMAC7.html)
WO (1) WO2017053170A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180063885A (ko) 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
CN109923123B (zh) * 2016-10-14 2024-01-23 爱默蕾大学 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
CN113912696B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与其应用
CN110669108A (zh) * 2019-09-06 2020-01-10 中国药科大学 一种多肽及其应用
EP4243852A4 (en) * 2020-11-13 2024-12-11 Ludwig Institute for Cancer Research Ltd PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY
CN118613277A (zh) * 2021-12-10 2024-09-06 乔治穆内公司 多肽调节物
CN115068496B (zh) * 2022-06-29 2023-07-07 四川大学 Dna四面体框架核酸和香蒲新苷的复合物及其制备治疗急性肾损伤的药物的用途
WO2024182318A2 (en) * 2023-02-28 2024-09-06 Kodiak Sciences Inc. Antibodies to htra1 and conjugates thereof
CN118256447A (zh) * 2024-04-26 2024-06-28 中国医学科学院北京协和医院 一种高转移能力的胰腺癌类器官及其构建方法和应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA149387A (en) 1913-05-22 1913-07-22 Andrew Jackson Coppock Means of priming explosive engines
CA151652A (en) 1913-08-23 1913-11-11 Per Erik Martin Norell Side bearing for cars
CA157738A (en) 1914-07-30 1914-09-08 John Martin Davis Aeroplane
DK100664C (da) 1960-05-11 1964-12-21 Friedrich Tonne Rørpostanlæg med automatisk styring af rørpostpatronernes bevægelse.
US5714166A (en) 1986-08-18 1998-02-03 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5629184A (en) 1995-01-25 1997-05-13 Amgen Inc. Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
CA2226299A1 (en) 1995-08-11 1997-02-27 Dendritech, Inc. Hyper comb-branched polymer conjugates
NZ500546A (en) 1997-04-14 2001-09-28 Cell Genesys Inc Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
US5948878A (en) 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
WO1999029303A1 (en) 1997-12-12 1999-06-17 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
ZA9811377B (en) 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6177274B1 (en) 1998-05-20 2001-01-23 Expression Genetics, Inc. Hepatocyte targeting polyethylene glyco-grafted poly-L-lysine polymeric gene carrier
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7595048B2 (en) * 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004033486A2 (en) * 2002-10-11 2004-04-22 Zymogenetics, Inc. Production of homotrimeric fusion proteins
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2006066066A2 (en) * 2004-12-15 2006-06-22 University Of North Carolina At Chapel Hill Chimeric vectors
NZ597168A (en) * 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
ES2657801T3 (es) 2007-07-10 2018-03-06 Apogenix Ag Proteínas de fusión de colectina de la superfamilia de TNF
WO2010037042A2 (en) * 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN102250254A (zh) 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
WO2012162426A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2765997A4 (en) * 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
RS58102B1 (sr) * 2011-11-09 2019-02-28 Bristol Myers Squibb Co Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom
SG10201601747XA (en) * 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
JP6707445B2 (ja) * 2013-10-21 2020-06-10 ジェネンテック， インコーポレイテッド 抗Ｌｙ６Ｅ抗体及び使用方法
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JP6731346B2 (ja) * 2014-02-10 2020-07-29 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
CN105085677B (zh) * 2014-05-05 2019-01-18 中国科学院上海药物研究所 抗vegfr2人源纳米抗体ntv1及其制备方法和用途
WO2016004389A2 (en) * 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
KR20180063885A (ko) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
CN108079301B (zh) 2016-11-23 2021-03-02 四川大学 减少cxcl13蛋白活性或表达量的活性物质在制备治疗恶性肿瘤转移药物中的用途
WO2018160572A1 (en) 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
CN112870362B (zh) * 2021-02-08 2023-06-27 中山大学附属第一医院 Circ-MET-1214和/或Circ-M50作为靶点在制备抗肿瘤药物中的用途
CN113234165B (zh) * 2021-05-07 2023-02-28 暨南大学 EpCAM的改造的结合蛋白及其应用
CN113402618B (zh) * 2021-06-30 2022-06-10 徐州医科大学 Ski在制备增效型CAR-T细胞中的应用
CN113512115B (zh) * 2021-08-09 2023-09-15 江苏省农业科学院 一种广谱识别小菜蛾中肠受体的抗Cry2Aa独特型单域抗体及其应用

Similar Documents

Publication Publication Date Title
JP2018534255A5 (cg-RX-API-DMAC7.html)
Liu et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects
Heidbuechel et al. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Barbari et al. Immunotherapies and combination strategies for immuno-oncology
ES3039539T3 (en) Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
Siegler et al. Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells
Wang et al. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma
CN111527109A (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
WO2015197016A1 (zh) 时空可调性抑制病理性靶细胞的系统
JP2021502810A5 (cg-RX-API-DMAC7.html)
CN113717942B (zh) 一种联合嵌合抗原受体和i型干扰素的免疫治疗方法及其应用
JP2017522025A5 (cg-RX-API-DMAC7.html)
JP2018509163A5 (cg-RX-API-DMAC7.html)
Pan et al. Monoclonal antibody 2C5-modified mixed dendrimer micelles for tumor-targeted codelivery of chemotherapeutics and siRNA
JP2020508662A (ja) 腫瘍形質導入のための組成物及び方法
Han et al. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors
CN108472365A (zh) 用于肿瘤转导的组合物和方法
CN111699000A (zh) 靶沉默技术的细胞内递送
Roddy et al. Novel cellular therapies for hepatocellular carcinoma
Schmidt et al. A killer choice for cancer immunotherapy
CN110564767A (zh) 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法
JP2015520172A5 (cg-RX-API-DMAC7.html)
Minayoshi et al. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
JP2020535811A5 (cg-RX-API-DMAC7.html)
Hamdan et al. Personalizing oncolytic virotherapy